Research Compendium/Selank
Brain & NootropicsResearch OnlyNot For Human Consumption

Selank

TP-7 · Tuftsin analogue

Anxiolytic peptide analogue of tuftsin with GABAergic and serotonin-modulating properties - no sedation or dependency profile.

MECHANISM OF ACTION

Selank is a synthetic heptapeptide derived from tuftsin, with Pro-Gly-Pro added to extend half-life. Anxiolytic mechanism: GABA-A receptor modulation (non-benzodiazepine site), enhanced 5-HT turnover in frontal cortex and hippocampus, and BDNF upregulation. Rodent models show no sedation, muscle relaxation, or amnesia at standard doses - distinguishing it from classical anxiolytics.

RESEARCH APPLICATIONS

  • Anxiolytic models without sedation or dependency
  • Serotonin metabolism research
  • GABA pathway modulation (non-BZD site)
  • Immunomodulation - NK cell activity
  • Cognitive performance under stress models

RESEARCH HIGHLIGHTS

GABAergic Anxiolysis Without Sedation

2010

Elevated plus-maze and open field tests show anxiolytic effects comparable to diazepam without sedation, motor impairment, or cognitive deficits.

Ref: Semenova et al., Psychopharmacology

5-HT Turnover Enhancement

2007

Intranasal Selank increased 5-HIAA/5-HT ratio in frontal cortex and striatum - enhanced serotonergic neurotransmission.

Ref: Filatova et al., Bulletin Exp Biol Med

RESEARCH PROTOCOL NOTES

Research format0.15% intranasal solution
Available formatsVial (10mg), Pen, Nasal Spray (7mg - VMed)
Stacked withSemax - complementary cognitive/anxiolytic profiles (Limitless Stack)

Chemical Identity

Molecular FormulaC33H57N11O9
Molecular Weight751.9 g/mol
CAS Number129954-34-3
Half-Life (t½)Minutes in plasma
SolubilitySoluble in water and saline

Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Storage & Stability

Lyophilised: -20°C. Solution: 2–8°C, 30 days. Similar to Semax.

Regulatory Status

Approved in Russia (0.15% nasal spray). No Western regulatory approval. Research compound. Not WADA prohibited.

Back to Research CompendiumView Research Compounds →